Axinn Obtains Favorable Decision in FDA Suit
January 15, 2013
Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc’s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.
Judge Huvelle’s Memorandum Opinion stated that “the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants.”
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
